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Functional inhibition of acid sphingomyelinase by
Fluphenazine triggers hypoxia-specific tumor cell death
Saskia Klutzny1,2, Ralf Lesche1, Matthias Keck1, Stefan Kaulfuss1, Andreas Schlicker1, Sven Christian1, Carolyn Sperl1,
Roland Neuhaus1, Jeffrey Mowat1, Michael Steckel1, Björn Riefke1, Stefan Prechtl1, Karsten Parczyk1 and Patrick Steigemann*,1
Owing to lagging or insufficient neo-angiogenesis, hypoxia is a feature of most solid tumors. Hypoxic tumor regions contribute to
resistance against antiproliferative chemotherapeutics, radiotherapy and immunotherapy. Targeting cells in hypoxic tumor areas is
therefore an important strategy for cancer treatment. Most approaches for targeting hypoxic cells focus on the inhibition of
hypoxia adaption pathways but only a limited number of compounds with the potential to specifically target hypoxic tumor regions
have been identified. By using tumor spheroids in hypoxic conditions as screening system, we identified a set of compounds,
including the phenothiazine antipsychotic Fluphenazine, as hits with novel mode of action. Fluphenazine functionally inhibits acid
sphingomyelinase and causes cellular sphingomyelin accumulation, which induces cancer cell death specifically in hypoxic tumor
spheroids. Moreover, we found that functional inhibition of acid sphingomyelinase leads to overactivation of hypoxia stress-
response pathways and that hypoxia-specific cell death is mediated by the stress-responsive transcription factor ATF4. Taken
together, the here presented data suggest a novel, yet unexplored mechanism in which induction of sphingolipid stress leads to
the overactivation of hypoxia stress-response pathways and thereby promotes their pro-apoptotic tumor-suppressor functions to
specifically kill cells in hypoxic tumor areas.
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Rapid cell growth and high metabolic rates of cancer cells in
combination with insufficient or disorganized neovasculariza-
tion can lead to the development of hypoxic or anoxic tumor
regions.1–3 Intratumoral hypoxia is a common feature of most
solid tumors2,4,5 and inversely correlates with clinical efficacy
of cancer therapies and clinical outcome.5–11 Therefore,
targeting cancer cells in hypoxic tumor areas is an important
strategy for cancer treatment.
One of the main strategies for targeting hypoxic tumor cells
is to inhibit or modulate hypoxia-survival pathways. Under
hypoxia, cancer cells activate different but partially over-
lapping stress-response pathways to adapt cellular metabo-
lism and promote pro-survival pathways.9 These include the
stabilization of hypoxia-inducible transcription factors (HIF),
the activation of endoplasmic reticulum (ER) stress pathways,
as well as the inhibition of mTOR signaling.12
Although hypoxic signaling via the known pathways is
relatively well characterized,9,13 less is known how hypoxia-
response pathways interact to orchestrate different hypoxic
responses and integrate other stress signals, for example, to
balance pro-survival and pro-apoptotic signals.14,15 Further-
more, apart from the canonical hypoxia pathways, little is
known about the adaptive mechanisms needed for cancer
cells to survive severe hypoxia. Accordingly, so far there are
only few drugs that act to specifically target hypoxic or anoxic
cells in tumors.8,16
Therefore, we established a screening-compatible HCT116
tumor spheroid model that mimics regions of severe hypoxia in
tumors and performed a phenotypic screen on a library of
known bioactive small molecules for the identification of
hypoxia-sensitizing compounds that specifically induce cell
death in hypoxic or anoxic tumor spheroids.
By this, we identified and validated GLUT or glycolysis
inhibition as potential strategy to specifically kill hypoxic cells.
Additionally, four highly hypoxia-selective compounds with
novel mode of action were identified that specifically induce
cell death in hypoxic spheroids and show no effects in spheroids
cultured under normoxia. Of these substances, Fluphenazine,
an antipsychotic phenothiazine drug, could be validated as
novel hypoxia-selective cell death inducer. Fluphenazine
induces lysosomal stress, functionally inhibits the lysosomal
enzyme acid sphingomyelinase (ASMase) and leads to the
accumulation of cellular sphingomyelin (SM). Moreover, SM
supplementation phenocopies the effects of Fluphenazine in
hypoxic spheroids. Importantly, Fluphenazine acts differently
than known lysosomal-disrupting agents17,18 or inhibitors of
lysosomal acidification.19 Furthermore, by deep sequencing we
show that Fluphenazine induces overactivity of hypoxia stress-
response pathways and causes hypoxia-specific cell death via
the stress-response transcription factor ATF4.
Results
Spheroids as in vitro model for tumor hypoxia. Fast
growth of cancer cells and lagging neo-angiogenesis can
lead to hypoxia in a large portion of the tumor, especially in
cells located distal to supplying blood vessels. Figures 1a
and b show the distribution of hypoxic areas in tumor
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Figure 1 HCT116 tumor spheroids incubated in hypoxia mimic hypoxic tumor regions distal from blood vessels in HCT116 xenografts. (a) IHC staining of HCT116 colon cancer
xenograft tumor sections. HCT116 tumor cryosections were stained for the exogenous hypoxia marker pimonidazole (Hypoxyprobe, green), CD31 as marker for blood vessel (red) and
the nuclear marker Hoechst (blue). Arrows indicate blood vessels. N= necrotic region. Dashed line showing region for measuring intensity profile in panel (b). Scale bar 100 μm. (b)
Line scan (dashed line in panel (a)) through HCT116 tumor section showing intensity profile of pimonidazole and CD31 staining. (c) Cryosections of HCT116 spheroids. Spheroids were
treated for 3 days in normoxia or hypoxia with or without the complex III inhibitor Antimycin (200 nM). Nuclei were stained by Hoechst (blue) and hypoxic areas with anti-pimonidazole
(green). Scale bar 100 μm. (d) Intensity profile pimonidazole staining (average of multiple spheroids, n= 5–10) from spheroid border to spheroid core region of HCT116 spheroids. (e)
Western blotting analysis of HCT116 spheroids incubated for 24 h in normoxia or hypoxia. Beta-actin was used as an internal control. Representative data of multiple experiments
shown (n= 3). (f) Real-time quantitative PCR gene expression analysis of HIF target genes in HCT116 spheroids incubated for 24 h in normoxia or hypoxia. Ct values of each sample
were normalized with the internal control RPL32 and normalized to the normoxia sample. Bars show mean with S.D. (n= 3). **** = P-value smaller 0.0001
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xenograft sections of HCT116 colon cancer cells with hypoxic
and dormant regions increasing with growing distance from
supplying blood vessels (see also1,9).
Hypoxic and nutrient-depleted conditions found in tumor
tissue can be mimicked in a 3D cell culture setting and tumor
spheroids are being increasingly used to better reflect
physiological conditions of tumor cell growth in vitro. To identify
compounds that specifically target cells in hypoxic or anoxic
tumor regions, we aimed to establish conditions of severe
hypoxia in HCT116 colon cancer tumor spheroids. Cryosec-
tions from HCT116 tumor spheroids cultured under normoxic
conditions show pimonidazole staining in the core region of the
spheroid. However, this region expands to the outer spheroid
cell layer in spheroids that were cultured in hypoxic conditions
(see Figure 1c and hypoxia profile in Figure 1d, seeMaterial and
Methods section for spheroid formation and incubation).
In tumor tissue, hypoxic gradients develop by cellular
respiration of intervening cells and promote the development
of hypoxic regions in cells distal from oxygen-supplying
blood vessels.1 Accordingly, pimonidazole staining of hypoxic
regions in HCT116 tumor spheroids is diminished after
addition of an inhibitor of cellular respiration (Figures 1c
and d), indicating that hypoxic gradients in spheroids are also
established by cellular oxygen consumption.
Additionally supporting the use of spheroids cultured under
hypoxia as model system for hypoxic tumor regions, HIF-1-α
shows strong accumulation in tumor spheroids cultured under
hypoxia while it is only faintly detected in normoxic conditions
(Figure 1e). Moreover, mRNA expression of HIF-1-α target
genes are upregulated in tumor spheroids cultured under
hypoxia (Figure 1f).
Taken together, these data show that HCT116 tumor
spheroids cultured in reduced oxygen conditions are strongly
hypoxic and activate hypoxia adaption pathways. Thus they
represent a suitable model system for the identification of
compounds that target tumor hypoxia or anoxia.
Screen for the identification of compounds that induce
hypoxia-specific cell death. We hypothesized that target-
ing hypoxia adaption pathways necessary for cellular survival
should induce cell death in HCT116 tumor spheroids
incubated under hypoxia, while showing less or no effect in
spheroids cultured under normoxia. In order to identify such
compounds, we established HCT116 tumor spheroid forma-
tion in screening-compatible 384-well microtiter plates (see
Materials and Methods section) and screened a drug library
of known bioactive substances on HCT116 colon cancer
spheroids cultured under hypoxia or normoxia (n=4 per
compound).
From 468 tested compounds, 43 induced a significant
increase in staining for cell death under hypoxia (at least 50%
intensity of dead cell staining normalized to controls). For 16 of
these compounds, cell death staining was at least two times
stronger under hypoxia compared with normoxia (for a
complete list of all tested compounds, see Supplementary
Table S1). Nine of the 16 hit compounds could be validated as
hypoxia specific, showing concentration-dependent cell death
induction under hypoxia and no effects or effects only at
significantly higher concentrations under normoxia (see
Table 1 and Supplementary Figure S2). To exclude cell-line-
specific effects, all confirmed hits were also profiled in T47D
breast cancer tumor spheroids and showed similar effects
(Supplementary Table S2).
Taken together, from 468 compounds of a known bioactives
library, 9 compounds could be identified as hypoxia-sensitizing
compounds, showing an increase in cell death staining
specifically when incubatedwith tumor spheroids under hypoxia.
GLUT or glycolysis inhibition induces hypoxia-specific
cell death. A major characteristic of cellular hypoxia is the
repression of the respiratory chain, which forces cells to
switch from cellular respiration to glycolysis for energy
production. Therefore, we speculated that hypoxia-specific
hits could act by sensitizing cells to hypoxia by interfering with
glycolysis. To identify such compounds, we tested the effects
of all hits under normoxia in co-incubation with a respiratory
chain inhibitor (complex III inhibitor Antimycin). Respiratory
chain inhibition renders cells dependent on glycolysis for
energy production and survival and co-incubation with a
glucose transport (GLUT) or glycolysis inhibitor leads to
synthetic lethality also under normoxia.20
Two compounds from the hit list, Cytochalasin B and E6
Berbamine, showed synthetic lethality on HCT116 spheroids
cultured under normoxia when incubated with Antimycin (see
Table 1 and Supplementary Figure S2). Indeed, Cytochalasin
B is a long-knownGLUT inhibitor.21 In order to verify glycolysis
as an important factor for cellular survival under hypoxia, we
also tested a glycolysis inhibitor (2-deoxy-D-glucose (2-DG))
and incubation in medium with low glucose. In both cases, we
found similar hypoxia-specific effects in HCT116 tumor
spheroids and synthetic lethality after co-incubation with
Antimycin under normoxia (Supplementary Figure S3).
Taken together, these data indicate that limiting glucose
supply or inhibition of glycolysis could be an option to kill cells
in hypoxic tumor areas. A detailed analysis of GLUT inhibitors
for cancer therapy is covered elsewhere,22–24 and we
concentrated our studies on the remaining hits with a novel
mode of action.
Hypoxia-sensitizing compounds alter cellular lipid com-
position by inhibiting ASMase. Seven of the identified hits
displayed a phenotype different from GLUT or glycolysis
inhibitors, showing no synthetic lethality in tumor spheroids
when co-incubated with Antimycin under normoxia (see
Supplementary Figure S2). However, three of these sub-
stances induced cell death or proliferation inhibition also in
hypoxic or normoxic 2D culture conditions and therefore were
not further evaluated (see Table 1). Strikingly, co-incubation
with the respiratory chain inhibitor Antimycin, which
prevents the establishment of hypoxic gradients in spheroids
(see Figure 1c), almost completely prevented induction of
cell death by the remaining four hit compounds in tumor
spheroids cultured under hypoxia (Table 1 and Supple-
mentary Figure S2).
The most potent compound of this novel class of hypoxia-
selective hits is Trifluoperazine (see Figure 2 and Table 1), an
antipsychotic of the phenothiazine class, which is known to
inhibit dopamine receptors.25 However, while other phenothia-
zines such as Fluphenazine, Chlorpromazine or Thioridazine
showed similar hypoxia-specific effects (see Table 1 and
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Table 1 Retest and EC50 generation of hypoxia specific hits in hypoxic and normoxic 3D tumor spheroids (without or with respiratory chain inhibitor Antimycin
(200 nM)) or in 2D culture (HCT116)
Compound 
EC50 (cell death) in tumor spheroids (M) EC50 (cell count) in 2D in (M) 
Hypoxia 
<1% O2
Nor-
moxia 
21% O2
Respira-
tory chain 
inh. at 
21% O2
Respira-
tory chain 
inh. at 
<1% O2 
Hypoxia 
<1% O2
Nor-
moxia 
21% O2
 Hypoxia-sensitizing compounds with novel mode of action  
Trifluoperazine 1.35E-06 
(SD 7.2E-07) >1E-05 >1E-05 >1E-05 > 1E-05 >1E-05 
*Fluphenazine 1.63E-06 
(SD 1.2E-06) >1E-05 >1E-05 >1E-05 > 1E-05 >1E-05 
ML9 2.79E-06 
(SD 2.0E-06) >1E-05 >1E-05 >1E-05 > 1E-05 >1E-05 
*Chlorpromazine 3.31E-06 
(SD 6.2E-07) >1E-05 >1E-05 >1E-05 > 1E-05 >1E-05 
Tamoxifen 3.44E-06
(SD 2.5E-06) >1E-05 >1E-05 >1E-05 > 1E-05 >1E-05 
ML7 3.92E-06 
(SD 1.6E-06) >1E-05 >1E-05 >1E-05 > 1E-05 >1E-05 
*Thioridazine 4.09E-06 
(SD 3.2E-06) >1E-05 >1E-05 >1E-05 > 1E-05 >1E-05 
GLUT inhibitors or not spheroid specific 
Cytochalasin B 5.67E-06 
(SD 2.3E-06) >1E-05 
2.52E-06
(SD 6.7E-07)
2.68E-06 
(SD 1.3E-07)
1.94E-06 
(SD 7.9E-08)
1.61E-06 
(SD 1.8E-07)
E6 Berbamine 2.09E-06 
(SD 3.4E-07)
9.04E-06 
(SD 9.4E-07)
2.4E-06 
(SD 6.8E-07)
2.38E-06 
(SD 4.4E-07)
2.83E-06 
(SD 4.7E-07)
5.85E-06 
(SD 9.2E-08)
Wiskostatin 2.16E-06 
(SD 1.2E-07) >1E-05 
9.11E-06
(SD 1.4E-06)
7.13E-06 
(SD 9.2E-07)
4.77E-06 
(SD 7.5E-07)
6.71E-06 
(SD 3.3E-06)
Latrunculin B 2.67E-06 
(SD 1.2E-06) >1E-05 >1E-05 >1E-06 
8.82E-07 
(SD 5.2E-07)
1.11E-06
(SD 2.1E-07)
GF-109203X 3.39E-06 
(SD 7.9E-07)
1.0E-05 
(SD 1.5E-13) >1E-05 >1E-05 
5.8E-06 
(SD 2.1E-06)
7.32E-06
(SD 9.5E-07)
HCT116 cells /spheroids were treated for 72 h in normoxic or hypoxic conditions. 3D tumor spheroids: Dead cells were stained with SytoxGreen and fluorescent
intensities in spheroidsweremeasured. Valueswere normalizedwith solvent (DMSO) control (0%) and Staurosporine (10 μM) as positive control (100%) for cell death.
2D culture: Nuclei were stained with Hoechst and cell counts were determined by automated image analysis and normalized with DMSO control (0). EC50 valueswere
determined in ≥ 3 independent experiments. Colored gradation of EC50 values, from white = inactive to dark green = strongest effect. *phenothiazine hit expansion
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Supplementary Figure S2), other structurally unrelated anti-
psychotics with activity against dopamine receptors, such
as Haloperidol, Amisulpride, Pimozide or Fluspirilene,26–29
showed no hypoxia-specific effects (data not shown). There-
fore, we speculated that these compounds specifically kill cells
in hypoxic tumor spheroid regions independently of their
known biological function. For further evaluation of hypoxia-
sensitizing compounds, we concentrated on Fluphenazine as
one of the most potent compounds with high hypoxia
specificity in spheroids (1.63 μM under hypoxia, 410 μM
under normoxia) (Table 1).
Based on the compound structure, many of the identified
hits, including Fluphenazine, can be characterized as ‘cationic
amphiphilic’ drugs (CAD) (see Supplementary Table S3).30
CADs can accumulate in lysosomes, cause lysosome
dysfunction and lysosome membrane permeabilization
(LMP).17,31,32 Accordingly, most identified hypoxia-sensiti-
zing compounds have been reported as lysosomotropic
substances.33–37
Therefore, we first investigated the impact of Fluphenazine
treatment on lysosomes. By Lamp2 antibody staining, a
lysosomal-associated protein, we found that Fluphenazine
leads to an aggregation of lysosomes (Figure 3a). Accordingly,
Fluphenazine treatment results in a dose-dependent accu-
mulation of acidic vesicles seen by Lysotracker staining at an
EC50 of 3.8 μM (S.D. 360 nM), (see Figure 3b).
Lysosomes are a major site of cellular phospholipid
metabolism. Lysosomal stress or damage induced by CADs
can induce phospholipidosis, the accumulation of
phospholipids in cells and tissues.30,38 To test for lysosome
functionality, we thereforemeasured the accumulation of lipids
using the LipidTOX Phospholipidosis Detection Kit. Fluphe-
nazine led to a dose-dependent accumulation (EC50 of
2.74 μM, S.D. 710 nM) of fluorescent phospholipids (see
Figure 3c). Similar results were obtained for Trifluoperazine,
Tamoxifen and ML9 (data not shown).
Taken together, these data indicate that Fluphenazine
impairs lysosomal functionality at concentrations required for
induction of cell death in hypoxic spheroids (compare with
Table 1).
To further investigate this, we profiled the metabolic
signature of 188 metabolites, including different lipids of
Fluphenazine-treated cells by mass spectrometry (see
Supplementary Figure S4). Fluphenazine treatment led to a
strong accumulation of SMs, phosphocholines (PCs) and
lysophosphatidylcholines (Figure 3d). SMs are a major
component of cellular lipid membranes. In lysosomes, they
are converted to ceramide and PC by the lysosomal enzyme
ASMase. Therefore, we speculated that Fluphenazine could
interfere with ASMase function. Indeed, cell extracts of
HCT116 cells treated for 24 h with Fluphenazine before
harvesting showed a reduction of ASMase activity
(Figure 3e). However, when cell extracts from untreated cells
or recombinant ASMase were treated with Fluphenazine, we
found no reduction in ASMase activity (data not shown).
Therefore, we conclude that Fluphenazine functionally inhibits
ASMase and leads to alterations in cellular sphingolipid
composition. Accordingly, exogenously added fluorescent
SM shows strong lysosomal accumulation after Fluphenazine
treatment (Figure 3f).
To test whether Fluphenazine-induced hypoxia-specific cell
death in spheroids could be a consequence of cellular SM
accumulation, tumor spheroids were incubated with different
concentrations of exogenously added SM. Indeed, exogenous
addition of N-Palmitoyl-D-Sphingomyelin (18:1/16) led to a
dose-dependent induction of cell death in hypoxic (58.4 μM,
S.D. 1.9 μM) but not in normoxic spheroids. Additionally,
similar to Fluphenazine treatment, co-treatment of SM with a
respiratory chain inhibitor led to a rescue of cell death
induction in tumor spheroids (Figure 3g). In contrast, the
addition of the direct SM metabolites ceramide or PC showed
no effect on cell viability nor did it prevent Fluphenazine-
induced cell death (data not shown). Taken together, we
conclude that hypoxia-specific induction of cell death in
spheroids is caused by cellular SM accumulation and not by
the accumulation of SM metabolites.
Fluphenazine functionally inhibits ASMase distinct from
known lysosomotropic substances. Interestingly, LMP
compounds such as Siramesine have been shown to inhibit
ASMase and have been proposed as anticancer drugs for the
treatment of multidrug-resistant cancers.17,18 By interfering
with lysosomal membrane integrity and ASMase membrane
localization, they are thought to act as functional inhibitors of
ASMase.32 However, as lysosomes are important organelles
that cover a wide range of cellular functions, disrupting
lysosomes in general will impair a variety of cellular functions
and has been proposed to be generally cytotoxic to most
cells.39 Indeed, we find that the LMP-inducing compound
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Figure 2 High-content screen on HCT116 spheroids identifies hypoxia-
sensitizing compounds. HCT116 spheroids were grown for 4 days in normoxic
conditions, followed by 3 days of compound treatment (DMSO control, Staurosporine
10 μM or Trifluoperazine 5 μM) in normoxia, hypoxia or hypoxia+Antimycin 200 nM.
Spheroid nuclei were stained with Hoechst (red) and dead cells were stained with
SytoxGreen (green). Hypoxia-sensitizing compound Trifluoperazine specifically
induces cell death in spheroids cultured under hypoxia. Representative images of
multiple experiments shown (n≥ 3). Scale bar 100 μm
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Figure 3 Fluphenazine induces lysosomal stress and inhibits ASMase. (a–c) HCT116 cells were treated for 24 h with either DMSO control or 5 μM Fluphenazine. Cells were
either stained for (a) lysosome marker Lamp2 (b) for acidic vesicles using Lysotracker or (c) for the accumulation of undigested phospholipids using the LipidTOX
phospholipidosis staining. Nuclei were stained with Hoechst. Quantification of stainings shown on right hand side. Bars show mean with S.D. (n= 3). **** = P-value smaller
0.0001. Scale bar 10 μm. (d) Metabolomics analysis of 188 endogenous metabolites identifies the accumulation of SMs in Fluphenazine-treated cells. For full profile, please see
Supplementary Figure S4. HCT116 cells treated for 24 h with 5 μM Fluphenazine (compared with DMSO control). Bars show mean with S.D. (n= 2, 4 replicates per experiment).
**** = P-value smaller 0.0001. lysoPC: lysophosphatidylcholine. (e) ASMase activity in HCT116 cells treated for 24 h with either DMSO control or 5 μM Fluphenazine shows
strong reduction after Fluphenazine treatment. Bars show mean with S.D. (n= 3). **** = P-value smaller 0.0001. (f) HCT116 cells were co-incubated overnight with either DMSO
control+1 μM BODIPY FL C12-Sphingomyelin or 5 μM Fluphenazine+1 μM BODIPY FL C12-Sphingomyelin. Nuclei were stained with Hoechst and Lysosomes with Lysotracker.
Scale bar 20 μm. (g) HCT116 spheroids were grown for 4 days under normoxic conditions, followed by 3 days of compound treatment (DMSO control, 5 μM Fluphenazine,
100 μM N-Palmitoyl-D-Sphingomyelin (18:1/16)) and incubation either in normoxia, hypoxia or hypoxia and 200 nM Antimycin. Spheroid nuclei were stained with Hoechst (red)
and dead cells were stained with SytoxGreen (green). Representative images of multiple experiments are shown (n≥ 3). Scale bar 100 μm
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Siramesine, as well as the V-ATPase inhibitor Bafilomycin A1,
which also generally disrupts lysosomal functions by pre-
venting lysosomal acidification,19 do not act as hypoxia-
sensitizing compounds as they induce cell death in spheroids
or in 2D cell culture under hypoxia or normoxia alike (see
Table 2 and Figure 4a). This strongly contrasts with the
ASMase inhibitor Fluphenazine, which is inactive in spher-
oids under normoxia and in 2D culture conditions (see
Table 1). Moreover, while Siramesine and Bafilomycin lead to
the formation of galectin puncta at lysosomes, which is an
indicator for LMP,40 this could not be detected in
Fluphenazine-treated cells (Figures 4b and c). Therefore,
we conclude that Fluphenazine targets lysosomal functions
without destabilizing lysosomal membranes.
Fluphenazine induces HIF overactivation in conditions of
high HIF background levels. We speculated that hypoxia-
sensitizing compounds such as Fluphenazine could induce
hypoxia-specific cell death in tumor spheroids by interfering
with hypoxia adaption pathways. The transcription factor
family of HIFs is selectively stabilized under hypoxia and
regulates the transcription of several genes important for a
cellular response to low oxygen levels.
We therefore asked whether hypoxia-sensitizing com-
pounds interfere with HIF signaling. For this, a HCT116
reporter cell line that expresses luciferase under the control of
a hypoxia-response element (HRE)41 was used to measure
HIF transcriptional activity (HRE-Luc assay; see Material and
Methods section). Although the reporter shows no activity
under normoxia, the signal increases significantly under
hypoxia or after co-incubation with the hypoxia-mimetic
Deferoxamine mesylate (DFO)42 (see Figure 5a). Interest-
ingly, Fluphenazine has no effect on the luminescence signal
under normoxia but shows an approximately two-fold stronger
signal compared with controls in conditions of high HIF
background activity (hypoxia or DFO treatment; see
Figure 5a and Supplementary Figure S5).
To further evaluate this, we measured the effect of
Fluphenazine on endogenous HIF target gene expression by
real-time quantitative PCR. Pro-survival (SLC2A3 (GLUT3) and
VEGFA) as well as pro-apoptotic HIF target genes (BNIP3)
were upregulated in HIF-stabilized conditions (DFO treatment),
while all measured mRNA levels showed no significant
expression level changes under normoxic growth conditions
upon Fluphenazine treatment (Figure 5b). Furthermore, similar
to Fluphenazine treatment exogenous SM supplementation led
to a 2.2-fold stronger luminescence signal compared with
controls in hypoxic conditions (Figure 5c). Therefore, we
conclude that Fluphenazine induces HIF transcriptional over-
activity in conditions of high HIF basal levels possibly by
inducing cellular SM accumulation.
HIF is regulated at different levels, including translational
and transcriptional control, as well as protein stability and
activity.16,43 Fluphenazine treatment did not lead to alterations
in HIF-1-α transcript levels (Figure 5d) and no differences in
HIF-1-α protein levels could be observed (Figure 5e). Hence,
we conclude that Fluphenazine leads to an activation of HIF-1-
dependent transcription, downstream of HIF-1-α protein
stabilization or accumulation, for example, on the level of
activity regulation by posttranslational protein modification or
interaction with transcriptional co-factors, such as ATF4.44
Fluphenazine induces stress-response pathways. To
obtain a broader picture of transcriptional regulation induced
by Fluphenazine, we determined the transcript level of all
protein-encoding genes (~20 000 genes) by deep sequen-
cing of HCT116 cells treated with either DFO or DFO together
with Fluphenazine.
As expected, among 559 significantly upregulated tran-
scripts (see Supplementary Figure S6) several known HIF-1-α
target genes (Supplementary Table S4) were identified.
Additionally, many central components of the ATF4- and
CHOP-dependent pro-apoptotic stress-response pathway
such as ATF4, DDIT3 (CHOP), PPP1R15A (GADD34),
ATF3, HERPUD1 and GADD45A45–48 were among the hits
that show the highest upregulation after Fluphenazine–DFO
co-treatment (see Figure 6a).15 We confirmed these results in
hypoxic tumor spheroids (Figure 6b), which show a strong
hypoxia-specific upregulation of ATF4 pro-apoptotic target
genes PPP1R15A (GADD34) and DDIT3 (CHOP) upon
Fluphenazine treatment. Taken together, we conclude that
Fluphenazine treatment induces the transcription of pro-
apoptotic cellular stress-response genes.
Hypoxia or cellular stress pathways such as the HIF- or
ATF4/CHOP-dependent pathway have been shown to activate
pro-survival as well as pro-apoptotic pathways, which are
balanced to determine cellular fate.15,47–49 Therefore, we
investigated the contribution of ATF4 or HIF signaling path-
ways to the induction of cell death in hypoxic spheroids. For
this, we knocked down ATF4, HIF-1-α or HIF-2-α and tested
whether this was sufficient to rescue Fluphenazine-induced
cell death (for knockdown efficacies, see Supplementary
Figure S7). Knockdown of ATF4 significantly reduced
Fluphenazine-mediated overactivation of ATF4 pro-apoptotic
target genes DDIT3 (CHOP) and PPP1R15A (GADD34)
under hypoxia (Figure 6c). Additionally, knockdown of ATF4
but not HIF-1-α or HIF-2-α partially rescued Fluphenazine- or
Table 2 Siramesine and Bafilomycin A1 induce tumor spheroid cell death
independently of oxygen levels
Compound 
EC50 (cell death) in     
tumor spheroids (M) 
 EC50 (cell count) in 
2D in (M)
Hypoxia 
<1% O2
Normoxia 
21% O2
Hypoxia 
<1% O2
Normoxia
21% O2
Siramesine 1.84E-06
(SD 1.1E-07)
5.82E-06
(SD 2.4E-06)
3.35E-06 
(SD 3.0E-07)
3.19E-06 
(SD 5.2E-07)
Bafilomycin <1E-08 <1.0E-08 <1.0E-08 <1.0E-08 
HCT116 cells /spheroids were treated for 72 h in normoxic or hypoxic conditions.
3D tumor spheroids: Dead cells were stained with SytoxGreen and fluorescent
intensities in spheroids were measured. Values were normalized with solvent
(DMSO) control (0%) and Staurosporine (10 μM) as positive control (100%) for cell
death. 2D culture: Nuclei were stained with Hoechst and cell counts were
determined by automated image analysis and normalized with DMSO control (0).
EC50 valueswere determined in≥3 independent experiments. Colored gradation
of EC50 values, from white = inactive to dark green = strongest effect
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SM-induced cell death in hypoxic spheroids (Figure 6d). This
indicates that hypoxia-specific cell death induced by Fluphe-
nazine is dependent on ATF4.
Discussion
We here used a tumor spheroid-based assay to mimic tumor
hypoxia and to screen for compounds that specifically kill cells in
hypoxic tumor spheroid regions. This approachwas validated by
the identification of the GLUT inhibitor Cytochalasin B aswell as
the glycolysis inhibitor 2-deoxyglucose as hypoxia-specific
inducers of spheroid cell death. Next to oxidative phosphoryla-
tion, glycolysis is one of the two main energy-producing
pathways in cells. In hypoxic tumor regions, respiration is
suppressed by the lack of oxygen and cells are rendered
dependent on glycolysis for energy production and survival.
Although inhibitors of glycolytic flux have been proposed as
potential approach for cancer therapy, high toxicity in highly
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Figure 4 Fluphenazine induces lysosomal stress distinct from known lysosomotropic substances. (a) HCT116 spheroids were grown for 4 days in normoxic conditions,
followed by 3 days of compound treatment (DMSO control, Fluphenazine 5 μM, Siramesine 5 μM or Bafilomycin 200 nM) and incubation either in normoxia or hypoxia. Spheroid
nuclei were stained with Hoechst (red) and dead cells were stained with SytoxGreen (green). Only Fluphenazine induces hypoxia-specific cell death. Representative images of
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Figure 5 Fluphenazine induces HIF overactivation in conditions of high HIF background levels. (a) HIF activity reporter cells HCT116-HRE-Luc were treated either with
DMSO control or 10 μM Fluphenazine and incubated for 16 h in normoxia, hypoxia or in normoxia with the HIF-PH inhibitor DFO. After incubation, cells were lysed and luciferase
activity was measured. Bars show mean with S.D. (n= 3). (b) HCT116 cells were treated for 24 h with or without DFO (1 mM) and additionally with either DMSO control or
Fluphenazine (5 μM). Gene expression analysis was performed for three HIF1 target genes (SLC2A3, VEGFA and BNIP3) by real-time quantitative PCR (RT-qPCR). hRP-L32
was used as reference gene and relative expression level were normalized to the untreated control (no DFO, DMSO). Bars show mean with S.D. (n= 3). (c) HCT116-HRE-Luc
cells were treated with either Ethanol control or 100 μM SM (18:1/16) and incubated for 24 h either in normoxia or hypoxia. After incubation, cells were lysed and luciferase activity
was measured (n= 3). (d) RT-qPCR analysis of HIF-1-a mRNA level of HCT116 Spheroids treated for 24 h in normoxia or hypoxia with either DMSO control or 5 μM
Fluphenazine. hRP-L32 was used as reference gene and the relative expression level were normalized with the untreated control (normoxia DMSO control). Bars show mean with
S.D. (n= 3). (e) Western blotting analysis of HIF-1-a protein expression in HCT116 spheroids or HCT116 cells grown in 2D that were treated for 24 h with either DMSO control or
5 μM Fluphenazine under normoxia, hypoxia or normoxia+1 mM DFO. Representative data of multiple experiments are shown (n= 3). Intensity values were normalized to
loading control and DMSO-treated controls under hypoxia (upper row) or DMSO controls co-incubated with DFO (lower row). Beta-actin was used as an internal control
(not shown). * = P-value between 0.01 and 0.05, ** = P-value between 0.001 and 0.01, *** = P-value between 0.0001 and 0.001, **** = P-value smaller 0.0001
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glucose-dependent tissues such as the brain, retina or testes
have been identified as a major challenge.9 Therefore, we
concentrated our studies on the remaining hypoxia-sensitizing
screening hits that displayed a phenotype different fromGLUTor
glycolysis inhibitors and induced hypoxia-specific cell death by a
potential novel mode of action.
Interestingly, all of these compounds showed ‘cationic
amphiphilic’ structural features characteristic for compounds
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Figure 6 Fluphenazine induces ATF4 overactivation in hypoxic spheroids. (a) Analysis of all protein-encoding genes by deep sequencing of HCT116 cells treated for 24 h
with either 1 mM DFO or 1 mM DFO+5 μM Fluphenazine (see also Supplementary Figure S6) showed upregulation of ATF4/CHOP-dependent stress-response pathway upon
Fluphenazine and DFO co-treatment. Bars show mean with S.D. (n= 1, median of 4 replicates). (b) Gene expression analysis (RT-qPCR) of ATF4 pro-apoptotic target genes in
HCT116 spheroids treated for 24 h in normoxia or hypoxia with DMSO control or 5 μM Fluphenazine. Ct values of each sample were normalized with the internal control RPL32
and normalized to the normoxia DMSO control. Bars show mean with S.D. (n= 3). (c) HCT116 cells were incubated with ATF4 siRNA or lipid only control and grown as spheroids
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genes PPP1R15A and DDIT3 were determined using RT-qPCR. Ct values of each sample were normalized with the internal control RPL32 and normalized to the hypoxia lipid
only control sample. Bars show mean with S.D. (n= 3). (d) siRNA-treated cells grown as spheroids (for ATF4) or spheroids from HCT116 cells stably transfected with HIF shRNA
(see Materials and Methods) were treated with either DMSO control or Fluphenazine (3 μM) (or 100 μM N-Palmitoyl-D-Sphingomyelin (SM d18:1/16)) for 3 days under hypoxia.
Spheroid nuclei were stained with Hoechst (red) and dead cells were stained with SytoxGreen (green). ATF4 ameliorates Fluphenazine- or SM-induced cell death under hypoxia.
n= 3. Scale bar 100 μm. ** = P-value between 0.001 and 0.01, *** = P-value between 0.0001 and 0.001
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that accumulate in lysosomes as a consequence of protona-
tion of their basic center in the acidic lysosome environment.30
Indeed, Fluphenazine, one of the most potent hypoxia-
selective compounds identified, leads to the accumulation of
lysosomes and impairs lysosomal functions such as phos-
pholipid metabolism by interfering with ASMase activity.
However, Fluphenazine acts differently than known inducers
of lysosomal dysfunction, such as Siramesine or Bafilomycin
A1. These compounds induce cytotoxicity in spheroids and 2D
cell culture independently of oxygen levels and cause LMP,
which could be the reason for their broader cytotoxic activity
and hypoxia-independent killing of cancer cells. Therefore, we
speculate that Fluphenazine functionally inhibits ASMase
without inducing LMP.
The main function of ASMase in lysosomes is to convert
SMs to ceramide and PC. Supporting the identification of
Fluphenazine as functional ASMase inhibitor, metabolomics
analysis of Fluphenazine-treated cells showed a strong
accumulation of SMs. Importantly, exogenous addition of SM
to the cell culture medium phenocopies the effect of
Fluphenazine in hypoxic spheroids. These findings support
the hypothesis that SM-induced lipid stress is the main cause
for the observed hypoxia-specific cell death and therefore
suggests SM metabolism as potential target for the therapy of
hypoxic tumors. However, cationic amphiphilic drugs such as
Fluphenazine are known to alter the biophysical properties of
cellular membranes and therefore could also affect other
pathways, especially at the high concentrations used in this
study. Accordingly, owing to the general compound toxicity we
were not able to achieve concentrations of Fluphenazine or
Trifluoperazine in vivo that would be sufficient to reach
concentrations required to induce cell death in hypoxic tumor
regions (data not shown).50
Alterations in cellular membrane lipid compositions, for
example, caused by impaired SM metabolism are known
to induce lipid stress, leading to activation of ER-stress
pathways, including ATF4 or XBP1 signaling.51 By deep
sequencing, we identified the upregulation of ATF4 transcripts
and ATF4 target genes after Fluphenazine treatment. Inter-
estingly, activation of ER-stress pathways is also one of
the main cellular responses to hypoxia.9 On the other
hand, hypoxia also leads to the stabilization of HIF transcrip-
tion factors. These signaling pathways are partially
overlapping12,44,52,53 and are balanced to either mediate a
pro-survival or a pro-apoptotic response, depending on the
severity of stress received.14,47,48,54,55 Fluphenazine treat-
ment or SM supplementation lead to an overinduction of
the hypoxia response, including both HIF and ATF4 transcrip-
tional overactivity, specifically in HIF-stabilized cells or
hypoxic spheroids. Therefore, a possible explanation for the
observed hypoxia-specific induction of cell death in spheroids
could be that simultaneous induction of hypoxia- and
lipid-stress pathways lead to alterations in hypoxia-stress
signaling, tipping the balance from a pro-survival to a pro-
apoptotic stress response (see Figure 7). Interestingly, we
find that cell death induction in hypoxic spheroids by
Fluphenazine is not dependent on HIF but on ATF4 transcrip-
tional activity.
Based on these findings, we propose a model in
which Fluphenazine induces cellular SM accumulation by
functionally inhibiting ASMase. Accumulation of SM in turn
induces lipid stress signaling by ATF4.51 Combining both, lipid
stress and hypoxic stress, shifts the balance of cellular stress
signaling to an ATF4-dependent pro-apoptotic response and
drives cells into apoptosis specifically in highly stressed
hypoxic or anoxic tumor cells (see Figure 7).
So far, most approaches to target hypoxic tumor cells have
focused to a great extent on the inhibition of hypoxia-stress
pathways.16 This has been owed to the fact that HIF-1 is
overexpressed in a large number of human tumors and
correlates with poor prognosis and treatment failure.56 Never-
theless, to date there is no clear clinical evidence of antitumor
activity due to HIF-1 inhibition9 and no specific HIF-1 inhibitor
has been clinically approved.8 In contrast, the here presented
data suggest a novel, yet unexplored, mechanism in which
induction of lipid stress could potentially lead to overactivation
of hypoxia-stress-response pathways and thereby promote
their pro-apoptotic tumor-suppressor functions to specifically
kill cells in hypoxic tumor areas.
Materials and Methods
Cell culture. All cell lines were obtained from American Type Culture Collection
(Manassas, VA, USA). HCT116 and T47D were cultured in RPMI 1640 (Gibco)
Supplemented with 10% FCS (PAA Laboratories by GE Healthcare, Little Chalfont,
UK) and 1% Penicillin/Streptomycin (Sigma-Aldrich, St. Louis, MO, USA) (and
0.01 μg/ml Insulin for T47D cells (Gibco by Thermo Fisher, Waltham, MA, USA)).
HCT116 cells carrying the HRE-Luciferase reporter construct (598-pGL3-Hif-RE-
Luc vector)41 were cultured in DMEM (Gibco) supplemented with 10% FCS, 1% PS
and 100 μg/ml Hygromycin B (Invitrogen, Carlsbad, CA, USA). Cells were
maintained at 37 °C in a 5% CO2 and 95% air incubator. Cells were subjected to
hypoxia by exposure too1% O2, 5% CO2 and balance N2 at 37 °C in an incubator
chamber (C16, Labotect, Rosdorf, Germany).
Immunohistochemistry: HCT116 tumor section. 1.5 × 106 human
colon cancer HCT116 cells were injected subcutaneously in cell medium into the left
flank of female NMRI nude mice (Charles River, Wilmington, MA, USA) to establish
a subcutaneous tumor. At a tumor size of an average of 100 mm2, the animals were
intravenously injected with Pimonidazole (Hypoxyprobe, Burlington, MA, USA)
according to the manufacturer’s instructions and killed 1 h later; the tumors were
resected and fixed in 10% formalin. The tumors were fixed in formalin for 48 h and
further processed in an Autotechnicon (Leica ASP 200S, Leica Biosystems,
Wetzlar, Germany), embedded in paraffin (Microm EC350-1, Thermo Fisher,
Waltham, MA, USA), sliced and generated sections were transferred to object
slides. Animal experiments were conducted in accordance with the German animal
welfare law, approved by local authorities and in accordance with the ethical
guidelines of Bayer AG.
Prior to immunostaining, slides were deparrafined using a decreasing alcohol
dilution series. Later, heat-mediated antigen retrieval was performed and unspecific
binding sides were reduced using Protein block (Dako by Agilent Technologies, Santa
Clara, CA, USA). Vasculature was stained using a 1:100 dilution of anti-CD31
(ab28364)) and 1:100 fluorescent Alexa 546 anti-rabbit secondary antibody (Jackson
ImmunoResearch, West Grove, PA, USA). Hypoxia was detected via bound
pimonidazole adducts using a 1:100 mouse–anti-pimonidazole–FITC (Hypoxyprobe,
HP6-100Kit). Additionally, tissue sections were stained with Hoechst 33342 (Life
Technologies by Thermo Fisher, Waltham, MA, USA) to label cell nuclei. Slides were
imaged for fluorescence on the ImageXpress Micro widefield imaging system
(Molecular Devices, Sunnyvale, CA, USA) with 10 × air objective and attached CCD
camera.
Spheroid generation. Spheroid generation was carried out using a modified
version of the liquid overlay cultivation technique described previously.57 Briefly,
10 μl of a heated 1.5% (w/v) agarose (in RPMI 1640, no FCS) solution was
dispended by a liquid dispenser (Multidrop Combi, Thermo Fisher, Waltham, MA,
USA) into sterile 384-well clear bottom imaging plates (Greiner, Kremsmuenster,
Austria). For spheroid growth, a single-cell suspension was seeded into agarose-
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coated 384-well clear bottom plates in 40 μl culture medium using a liquid
dispenser. Plates were incubated under standard cell culture conditions at 37 °C
and 5% CO2 in humidified incubators for 4 days. To obtain spheroids with an
approximate diameter of 400 μm on day 4, 300 cells were seeded per well for
HCT116 and 2000 cells per well for T47D. This setup led to the formation of one
spheroid per well with high intra-well and intra-plate reproducibility concerning
spheroid area and roundness (Supplementary Figure S1).
Immunohistochemistry: Spheroids. Three hours prior to harvest,
spheroids were incubated with 100 μM pimonidazole (Hypoxyprobe) under previous
culture conditions. After 2 h pimonidazole incubation, spheroids were fixed for 1 h in
4% PFA. Later, spheroids were transferred to 50 ml tubes, washed in DPBS
(Dulbecco’s Phosphate Buffered Saline) and equilibrated in 30% sucrose/ 5%
glucose (w/v) DPBS solution for 1 h. Then spheroids were transferred to cryomolds,
excess DPBS solution was removed and spheroids were covered in Tissue-Tek
OCT compound (Sakura, Staufen, Germany). After equilibration, cryomolds were
frozen by incubation in a mixture of dried ice and 2-Methylbutane (Sigma-Aldrich).
Prepared samples were cut into 5 μm sections by cryostat and mounted on
SuperFrost Plus slides (Menzel-Glaser, Braunschweig, Germany). Visualization of
hypoxic areas was carried out using a mouse FITC-MAb against pimonidazole
(Hypoxyprobe). Furthermore, sections were counterstained with Hoechst 33342
(Life Technologies) to stain nuclei. Slides were imaged on the ImageXpress Micro
widefield imaging system (Molecular Devices) with 10 × air objective and attached
CCD camera.
Compound treatment. After 4 days of spheroid growth, 20 μl culture medium
containing 80 nl compounds (ENZO Screen-Well ICCB Known Bioactives library,
Enzo Life Sciences, Farmingdale, NY, USA (468 compounds), final compound
dilution of 0.1–20 μM, depending on original stock concentration) were added and
incubated for additional 3 days either at normal culture conditions (21% O2, 37 °C,
5% CO2) or in a hypoxic chamber (o1% O2, 37 °C, 5% CO2). A 0.2% DMSO
solution was used as solvent control and Staurosporine (Sigma-Aldrich) as general
toxic control (10 μM).
Screening hits and further tool compounds, including Staurosporine, Antimycin A, 2-
DG, Fluphenazine, Chlorpromazine, Thioridazine, Clozapine, Bafilomycin A, Siramesine,
N-Palmitoyl-D-sphingomyelin, SM (from bovine brain), Ceramide (from bovine spinal
cord) and 2-Dioleoyl-sn-glycero-3-phosphocholine (18:1 (Δ9-Cis) PC), were purchased
from Sigma-Aldrich. 1-Stearoyl-2-arachidonoyl-sn-glycero-3-phosphocolin (18:0–20:4
PC) and 1-stearoyl-2-docosahexaenoyl-sn-glycerol-3-phosphocolin (18:0–22:6 PC)
were purchased from Avanti Lipids (Alabaster, AL, USA). All compounds, except for
SM and PCs, were dissolved in DMSO (10 mM) and stored at − 20 °C. SM and PCs
were dissolved in ethanol. Hypoxia mimicking agent DFO (Sigma-Aldrich) was used at a
final concentration of 1 mM (2D growth assays for 16–24 h).
Image acquisition and analysis of spheroids. Prior to imaging,
spheroids were stained for a minimum of 2 h by adding Hoechst 33342 (Life
Technologies) as counterstain for all nuclei and SytoxGreen as stain for dead cells
(Life Technologies) at a final dilution of 1:10 000 each. This set up led to a high
intra-well and intra-plate reproducibility concerning spheroid size and dead cell
staining (Supplementary Figure S1).
One image per spheroid and wavelength, focused on the spheroid center, was
captured by an Opera confocal spinning disc microscope system with a 4 × air
objective. Quantification of spheroid cell death was carried out with the MetaXpress
software (Molecular Devices) using custom written image analysis routines as
described previously.57
Normalization, quality control and fitting curves for EC50 determination of tested
compounds were carried out with Genedata Screener for high-content screening and
Genedata Condoseo modules (Genedata AG, Basel, Switzerland). In detail, wells
with no recognizable spheroid were masked and the average intensity of the dead cell
signal (SytoxGreen) was normalized to the DMSO control (0%) and the 10 μM
Staurosporine (100%) control.
The pilot screen performance was characterized by a robust RZ factor of 0.65.
Real-time quantitative PCR. Total RNA was isolated from HCT116 cells or
spheroids using RNeasy Plus Mini Kit (Qiagen, Venlo, Netherlands) and reverse-
transcribed with the RevertAid H Minus First Strand cDNA Synthesis Kit (Thermo
Fisher) according to the manufacturer’s instructions. To measure the expression
levels of target genes, sample concentrations were adjusted to 10 ng/μl cDNA and
mixed with specific TaqMan Gene Expression Primer (Thermo Fisher) and TaqMan
Fast Advanced Master Mix (Thermo Fisher). Real-time quantification was performed
in quadruplicates on a MicroAmp optical 384-well reaction plate (Thermo Fisher)
using a 7900 PCR machine (Applied Biosystems by Thermo Fisher, Waltham, MA,
USA). Relative mRNA levels were calculated to the geometric mean of reference
gene RPL32 (encoding ribosomal protein L32).
TaqMan Primers used were: RPL32 (ribosomal protein L32. Hs00851655_g1),
SLC2a3 (solute carrier family 2 (facilitated glucose transporter), member 3, encoding
Glut3 protein, Hs00359840_m1), VEGFA (vascular endothelial growth factor A,
Hs00900055_m1), BNIP3 (BCL2/ adenovirus E1B 19kDa interacting protein 3,
Hs00969291_m1), PPP1R15A (Protein phosphatase 1 regulatory subunit 15A,
Hs00169585_m1), DDIT3 (DNA-damage-inducible transcript 3, Hs99999172_m1),
ATF4 (Activating transcription factor 4, Hs00909569_g1), HIF-1-α (Hypoxia inducible
factor 1 alpha, Hs00153153_m1), and EPAS1 (Endothelial PAS domain-containing
protein 1, Hs01026149_m1).
Lipidomics analysis. After compound treatment for 24 h at 37 °C and 21%
O2 (n= 3), HCT116 cells were washed twice with cold sodium chloride (0.9%) and
incubated for 15 min with 1 ml 80% methanol at − 80 °C. Subsequently, cells were
harvested using a cell scraper and transferred together with the methanol into a new
tube. Wells were washed once with 500 μl 80% methanol and added into the same
tube. The resulting extracts were freeze-dried and resolved in 100 μl 100%
methanol followed by a centrifugation step. Later, 10 μl of these extracts were used
for target metabolite profiling by using the LC-MS based AbsoluteIDQ p180 Kit
(Biocrates Life Sciences AG, Innsbruck, Austria). All samples were processed
according to the manufacturer’s instruction, and measurements were performed with
a UHPLC-MS/MS System (Shimadzu UHPLC, Shimadzu, Kyoto, Japan and Sciex
5500 mass spectrometer, Sciex, Framingham, MA, USA). Multivariate data analysis
was carried out by using the Umetrics SIMCA-P software (MKS Data Analytics
Solutions, Malmö, Sweden).
Deep sequencing. HCT116 cells were seeded in 12-well plates and treated
for 24 h with either Fluphenazine (5 μM) alone or with Fluphenazine+DFO (1 mM)
at 37 °C and 21% O2 (n= 4). Total RNA of each sample was extracted using the
RNeasy Plus Mini Kit (Qiagen) according to the manufacturer’s instructions.
Subsequently, the TruSeq RNA Sample Preparation Kit v2 (Illumina, San Diego, CA,
USA) was used to convert the mRNA of each sample into a library of template
molecules for DNA sequencing. Briefly, poly-A containing mRNA molecules were
purified using oligo-dT attached magnetic beads. This was followed by mRNA
fragmentation using divalent cations and subsequent first-strand (reverse
transcriptase and random primers) and second-strand cDNA synthesis (DNA
Polymerase I and RNase H). The synthesized cDNA fragments then went through
an end repair process, the addition of a single ‘A’ base and ligation of the adapters.
Library quality was evaluated using the Agilent DNA 1000 Chip Kit (Agilent
Technologies, Santa Clara, CA, USA) and DNA quantity was determined using the
KAPA Library Quantification Kit (Kapa Biosystems, Wilmington, MA, USA) according
to the manufacturer’s instructions. All libraries were pooled and adjusted to a final
concentration of 10 nM before they were sequenced according to standard protocols
for the Illumina HiSeq 2500. Briefly, using the HiSeq SBS Reagent Kit v4 the sample
cDNA library was denatured, mixed with HT1 and adjusted to 18 pM. The sample
library was then mixed with a PhiX Library and applied to a HiSeq v4 flow cell
(Illumina), which was subsequently clustered on a cBot (Illumina) using the HiSeq v4
PE Cluster Kit (Illumina) before all samples were sequenced in the HiSeq 2500
system. On average 39± 6 million clusters were sequenced per sample. Reads were
mapped to the human genome (version hg19) using STAR aligner (version 2.4.2) and
read counts were assigned to 20776 annotated genes (gencode v19).
Statistical analysis was performed using the R statistical programming
environment version 3.1.2. The standard workflow implemented in the DESeq258
package version 1.6.3 was employed for identifying differentially expressed genes
between samples treated with DFO and FP compared with samples treated only with
DFO. Genes not expressed in any sample were removed before analysis. Genes
were defined as differentially expressed if they showed a fold change42 in either of
the conditions and had a Benjamini–Hochberg corrected P-value o0.05. Fisher’s
Exact test was used to identify Hallmark gene signatures from the Molecular
Signatures Database59 version 5.1 overlapping with the list of genes significantly
upregulated with treatment of DFO+FP compared with treatment with DFO alone.
Hallmarks with a Benjamini–Hochberg corrected P-value o0.05 were regarded as
significantly overlapping.
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Western blotting. Protein levels of HIF-1-α in HCT116 under various
treatment conditions were obtained via western blotting. Briefly, HCT116 cells
were either seeded in 2D in 6-well plates or on 384-well agarose-coated plates for
spheroid formation (4 days). After overnight incubation (2D) or 4 days of spheroid
growth, cells were treated with the compounds (DMSO control, Fluphenazine 5 μM)
under different conditions (Normoxia, Hypoxia or Normoxia+1 mM DFO). After
treatment, cells or spheroids were collected, lysed for 10 min with cold lysis buffer
(0.5 M Tris-HC, pH 7.4, 1.5 M NaCl, 2.5% deoxycholic acid, 10% NP-40, 10 mM
EDTA; Merck Millipore, Billerica, MA, USA) containing protease and phosphatase
inhibitor (Thermo Fisher). The lysate was centrifuged for 10 min at 4 °C (14 000 r.p.
m.), and the supernatant was collected for determining the protein content of each
probe using the Pierce BCA Protein Assay Kit with a BSA standard (Thermo Fisher)
according to the manufacturer’s instructions. Proteins were separated using 4–12%
Bis-Tris gels (Invitrogen) according to the manufacturer’s instructions. Later, the
separated proteins were transferred to nitrocellulose membranes (Life Technologies)
using an iBlot gel transfer device (Life Technologies). The membranes were blocked
for 1 h in 5% milk and later washed with 1 × TBST-Buffer (Carl Roth, Karlsruhe,
Germany).
Following the blocking procedure, blots were incubated overnight at 4 °C with the
primary antibodies, anti-HIF1-a (Abcam ab51608, Cambridge, UK) 1:200 and anti-
beta-actin (Sigma-Aldrich A5316) 1:3000. For quantification, blots were washed with
TBST and the membranes were incubated with an IRDye 680RD-anti-mouse IgG
(Licor, Lincoln, NE, USA) or an IRDye 800CW-anti-rabbit IgG (Licor). Blots were
imaged using an Odyssey CLx Imaging System (Licor). Quantification of bands was
performed using Image Studio Lite Ver. 4 (Licor).
Immunofluorescence. After formaldehyde fixation with 4% PFA, cells were
permeabilized with 0.1% Triton-X100 (Sigma-Aldrich) and unspecific binding sides
were blocked using 1% BSA. Mouse anti-Lamp2 (Santa Cruz Biotechnology sc-
18822, Dallas, TX, USA, 1:200) and rabbit anti- Galectin 1 (Abcam ab25138, 1:250)
were used as primary antibodies and appropriate secondary antibodies conjugated
with Alexa-Fluor 488 (Jackson ImmunoResearch) were used. Cell nuclei were
stained with Hoechst 33342 (Life Technologies). Images were acquired by an Opera
confocal spinning disc microscope system with a 40 × water objective.
Quantification of Galectin or Lamp2 staining (granules per cell and/or granules
intensity) was carried out with the MetaXpress software (Molecular Devices).
LipidTOX Phospholipidosis assay. To visualize phospholipid accumula-
tion in lysosomes, the LipidTOX Red Phospholipidosis Detection Reagent (Thermo
Fisher, 1:2000) was added to the cells with compound treatment according to the
manufacturer’s instructions. After 24 h incubation at standard cell culture conditions,
Hoechst 33342 (Life Technologies) was added to the cells at a final dilution of
1:5000. Images were acquired using the ImageXpress Micro widefield imaging
system (Molecular Devices) with a × 40 magnification. Quantification of phospholipid
accumulation (granules per cell and/or granules intensity) was carried out with the
MetaXpress software (Molecular Devices).
Lysotracker assay. After 24 h compound treatment, LysoTracker Red
DND-99 (Thermo Fisher) and Hoechst 33342 (Life Technologies) were added to
the cells at a final dilution of 1:2000 and 1:5000. Cells were incubated with the
staining reagent for 30 min at 37 °C before they were imaged using the
ImageXpress Micro widefield imaging system (Molecular Devices) with a × 40
magnification. Quantification of lysosomes (granules per cell and/or granules
intensity) was carried out with the MetaXpress software (Molecular Devices).
ASMase assay. After 24 h compound treatment, HCT116 cells were lysed by
performing multiple freeze–thaw cycles. The lysate was centrifuged for 10 min at
4 °C (14 000 r.p.m.) and the supernatant was collected for determining the protein
content of each probe using the Pierce BCA protein assay kit with a BSA standard
(Thermo Fisher) according to the manufacturer’s instructions. Subsequently, the
activity of ASMase was measured using the Echelon Acid Sphingomyelinase Assay
Kit according to the manufacturer’s instructions. Briefly, 20 μg per 20 μl sample or
diluted standards were added to a 96-well plate and mixed with 30 μl substrate
buffer. Afterwards, 50 μl diluted fluorogenic ASMase-specific substrate were added,
and the plate was incubated at 37 °C for 3 h with shaking before it was further
diluted and incubated for 10 min with 50 μl stop buffer. Subsequently, fluorescence
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Figure 7 Model for Fluphenazine-induced hypoxia-specific cell death by potentiating the pro-apoptotic path of cellular stress-response pathways. Fluphenazine impairs
lysosomal functions by interfering with ASMase activity. Sphingolipid accumulation induces ATF4 and CHOP. Incubation under hypoxia induces additional stress response and
additionally activates HIF1 transcriptional activity. Both transcription factors, ATF4 and HIF1, express pro-survival as well as pro-apoptotic genes that must be balanced to
determine cellular fate depending on the amount of stress received. Together, Fluphenazine and hypoxia treatment shift the cells’ stress response toward apoptosis and cell death.
However, either of these treatments alone is not sufficient to induce cell death and favors the pro-survival stress-response pathway. FP, Fluphenazine; C, ceramide; ASMase, acid
sphingomyelinase; ER, endoplasmic reticulum, SM, sphingomyelin
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levels were determined using a Tecan Plate reader (Tecan Trading AG, Männedorf,
Switzerland).
BODIPY FL C12-Sphingomyelin. To visualize cellular SM uptake and
localization, the fluorescent reagent BODIPY FL C12-Sphingomyelin (Thermo Fisher,
1 mM) was added to the cells with compound treatment. After 24 h incubation at
standard cell culture conditions, Hoechst 33342 (Life Technologies) was added to the
cells at a final dilution of 1:5000. Additionally, lysosomes were stained using
LysoTracker Red DND-99 (Thermo Fisher, 1:2000). Images were acquired by an
Opera confocal spinning disc microscope system with a 40 × water objective.
HRE-Luciferase reporter assay. To study HIF signaling, a HCT116
reporter cell line was used that is transfected with a 598-pGL3-HIF-RE-Luc reporter
plasmid that contains a luciferase gene expressed under the control of a VEGF
promoter-derived HRE.41 Cells were selected using 100 μg/ml Hygromycin B
(Invitrogen). Luciferase activity was measured using the luminescence kit Steady-
Glo (Promega, Fitchburg, WI, USA) and a luminescence plate reader (PHERAstar
(BMG Labtech, Ortenberg, Germany)) according to the manufacturer’s instructions.
Briefly, HCT 116-HRE-Luc cells were plated at 3000 cells/5 μl in white 384-well
small volume plates (Greiner) using a liquid dispenser (Multidrop Combi, Thermo
Scientific), 5 μl compounds were added and cells were either incubated in a normal
incubator or in a hypoxia chamber at41% O2 for 16 to 24 h. In all, 5 μl SteadyGlo
(Promega) were then added to cells and incubated for 30 min in the dark.
Subsequently, luminescence intensity was measured in a plate reader.
siRNA and shRNA transfection. To generate ATF4 knockdown cells,
HCT116 cells were incubated with ATF4 siRNA (Thermo Fisher s1703, 10 nM) and
Lipofectamine RNAiMAX (Thermo Fisher, 1:1000) lipid or control (lipid only) in
agarose-coated 384-well plates and grown as spheroids for 3 days at 37 °C and
21% O2 (see ‘Spheroid generation’). To generate HIF-1-α and EPAS1 knock-
down cells, HCT116 cells were stably transfected with shRNA (Sigma-Aldrich,
TRCN0000318674 and TRCN0000003803). Cells were selected using 0.6 μg/ml
Puromycin (Sigma-Aldrich) and subsequently grown to spheroids in agarose-coated
384-well plates for 4 days at 37 °C and 21% O2.
Statistical analysis. For statistical analysis, the Prism Scientific Presentation
Software (GraphPad Software, La Jolla, CA, USA) was used. Values were
compared by applying a two-tailed t-test with Welch’s correction. The statistical
significance between two levels is represented by asterisks (*P-value between 0.01
and 0.05; **P-value between 0.001 and 0.01; ***P-value between 0.0001 and 0.001
and ****P-value o0.0001). Error bars in graphs represent S.D.
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